Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Golimumab (Simponi IV — Janssen Inc.) indication: rheumatoid arthritis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0351. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that intravenous (IV) golimumab be listed for use in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), if conditions are met. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoids; Canada; Disease Progression; Drug Evaluation; Drug Therapy, Combination; Treatment Outcome; Tumor Necrosis Factor-alpha Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000179 Date abstract record published 03/03/2015 |